You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune check point inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Physical Activity and Exercise in Cancer Immunotherapy Treatment

Not yet recruiting
  • Cancer
  • Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions
  • (no location specified)
Nov 22, 2023

Acral Melanoma, Mucosal Melanoma Trial in Seoul (Pembrolizumab, Vactosertib)

Not yet recruiting
  • Acral Melanoma
  • Mucosal Melanoma
  • Pembrolizumab, Vactosertib
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Jun 23, 2022

Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Peking, Beijing, China
    Department of radiation oncology, Peking University Third Hospit
Jun 20, 2023

Locally Advanced Head Neck Cancer Trial in Kuwait (Pembrolizumab)

Recruiting
  • Locally Advanced Head and Neck Cancer
  • Kuwait, Kuwait
    Kuwait Cancer Control Center
Apr 13, 2021

Squamous Cell Head and Neck Carcinoma Trial (Durvalumab, radiotherapy, Placebo)

Withdrawn
  • Squamous Cell Head and Neck Carcinoma
  • (no location specified)
May 6, 2021

Adverse Events in Patients Treated With Immune Check Point

Recruiting
  • Immune-related Adverse Event
  • Antiinflammatory/DMARDs
  • Kristiansand, Norway
  • +4 more
Sep 15, 2022

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

Breast Cancer, Metastatic Breast Cancer, Breast Tumor Trial in Port Jefferson Station (SV-BR-1-GM, Cyclophosphamide, Interferon

Not yet recruiting
  • Breast Cancer
  • +4 more
  • SV-BR-1-GM
  • +4 more
  • Port Jefferson Station, New York
    New York Cancers & Blood Specialists
Oct 2, 2023

The Status of Immune Checkpoints at Gastrointestinal Cancer

Completed
  • Gastrointestinal Cancer
  • Flow cytometric analysis
  • Istanbul, Turkey
    Istanbul Training and Reseach Hospital
Dec 4, 2022

Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma Trial in Jerusalem

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Jerusalem, Israel
    Sharett institute, Hadassah University Hospital - Ein-Kerem
Nov 8, 2021

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Checkpoint Inhibitor Response

Active, not recruiting
  • NSCLC
  • +4 more
  • Breathprint analysis and patient-reported outcomes
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 24, 2022

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma Trial in Worldwide (EO2401)

Recruiting
  • Adrenocortical Carcinoma
  • +2 more
  • EO2401
  • Houston, Texas
  • +9 more
Dec 7, 2021

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In

Recruiting
  • Lung Cancer
  • +2 more
  • Standard of care immune checkpoint inhbitors
  • Fairway, Kansas
  • +1 more
Sep 19, 2022

Serial PET MPI in Patients Undergoing Cancer Treatment

Enrolling by invitation
  • Cancer
  • +3 more
    • Los Angeles, California
      West Los Angeles VA Medical Center
    Jun 12, 2023

    Glioblastoma, Adult Trial in Worldwide (Multiple dose of EO2401)

    Recruiting
    • Glioblastoma, Adult
    • Multiple dose of EO2401
    • Boston, Massachusetts
    • +9 more
    Dec 7, 2021

    Hepatocellular Carcinoma Trial in Hong Kong (Radiofrequency ablation or microwave ablation)

    Recruiting
    • Hepatocellular Carcinoma
    • Radiofrequency ablation or microwave ablation
    • Hong Kong, Hong Kong
      Chinese University of Hong Kong
    Feb 27, 2022

    Primary and Metastatic Tumors in Renal Cell Carcinoma and

    Recruiting
    • Renal Cell Carcinoma
    • +4 more
    • Immune checkpoint inhibitor targeting PD1
    • Philadelphia, Pennsylvania
      Fox Chase Cancer Center - Philadelphia
    Jan 27, 2023

    Responsiveness in Oncology Patients Based on Host Response

    Recruiting
    • Non Small Cell Lung Cancer
    • Healthy
    • blood, stool and tissue samples collection
    • Dallas, Texas
      Baylor Scott and White Research Institute
    Feb 9, 2023

    Pheochromocytoma, Metastatic, Pheochromocytoma Malignant, Paraganglioma, Malignant Trial in Beijing (Penpulimab)

    Recruiting
    • Pheochromocytoma, Metastatic
    • +2 more
    • Beijing, China
      Peking Union Medical College Hospital
    May 31, 2023

    Advanced Malignant Solid Tumor Trial in Sacramento (CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc,

    Terminated
    Has Results
    • Advanced Malignant Solid Neoplasm
    • CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
    • Placebo Administration
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Mar 8, 2022

    Medical Oncology, Integrative Oncology, Medical Nutrition Therapy Trial in Buffalo (Diet)

    Recruiting
    • Medical Oncology
    • +2 more
    • Diet
    • Buffalo, New York
      University at Buffalo / Great Lakes Cancer Care
    Jul 25, 2022

    NSCLC Trial in Buderim, Adelaide (6-Thio-2'-Deoxyguanosine, Cemiplimab)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Buderim, Queensland, Australia
    • +1 more
    Jul 5, 2022

    Papillary Renal Cell Carcinoma Type 2 Trial in France (Axitinib Oral Tablet [Inlyta], Pembrolizumab Injection [Keytruda])

    Recruiting
    • Papillary Renal Cell Carcinoma Type 2
    • Axitinib Oral Tablet [Inlyta]
    • Pembrolizumab Injection [Keytruda]
    • Angers, France
    • +11 more
    Aug 26, 2022